首页> 外文期刊>Plant Biotechnology Journal >Biochemical composition of haemagglutinin-based influenza virus-like particle vaccine produced by transient expression in tobacco plants
【24h】

Biochemical composition of haemagglutinin-based influenza virus-like particle vaccine produced by transient expression in tobacco plants

机译:烟草植物中瞬时表达产生的血凝素的流感病毒样颗粒疫苗的生物化学组成

获取原文
获取原文并翻译 | 示例
           

摘要

Influenza virus-like particles (VLPs) are noninfectious particles resembling the influenza virus representing a promising vaccine alternative to inactivated influenza virions as antigens. Medicago inc. has developed a plant-based VLP manufacturing platform allowing the large-scale production of GMP-grade influenza VLPs. In this article, we report on the biochemical compositions of these plant-based influenza candidate vaccines, more particularly the characterization of the N-glycan profiles of the viral haemagglutinins H1 and H5 proteins as well as the tobacco-derived lipid content and residual impurities. Mass spectrometry analyses showed that all N-glycosylation sites of the extracellular domain of the recombinant haemagglutinins carry plant-specific complex-type N-glycans having core (1,3)-fucose, core (1,2)-xylose epitopes and Lewis(a) extensions. Previous phases I and II clinical studies have demonstrated that no hypersensibility nor induction of IgG or IgE directed against these glycans was observed. In addition, this article showed that the plant-made influenza vaccines are highly pure VLPs preparations while detecting no protein contaminants coming either from Agrobacterium or from the enzymes used for the enzyme-assisted extraction process. In contrast, VLPs contain few host cell proteins and glucosylceramides associated with plant lipid rafts. Identification of such raft markers, together with the type of host cell impurity identified, confirmed that the mechanism of VLP formation in planta is similar to the natural process of influenza virus assembly in mammals.
机译:流感病毒样颗粒(VLP)是非缺陷的颗粒,类似于流感病毒,其代表具有灭活流感病毒粒子作为抗原的有前途的疫苗替代物。 Medicago Inc。开发了一种基于工厂的VLP制造平台,可以大规模生产GMP级流感VLP。在本文中,我们报告了这些基于植物的流感候选疫苗的生化组合物,更具体地说是病毒血凝素H1和H5蛋白的N-聚糖谱的表征以及烟草衍生的脂质含量和残留杂质。质谱分析表明,重组血凝素细胞外结构域的所有N-糖基化位点携带具有核心(1,3)的植物特异性复合型N-聚糖 - 糖,核心(1,2) - Xylose Epitopes和Lewis( a)扩展。先前的阶段I和II临床研究表明,观察到没有对这些聚糖指导的IgG或IgE的过度敏性也不感应。此外,本文表明,植物制造的流感疫苗是高度纯纯VLPS制剂,同时检测来自农杆菌的蛋白质污染物或来自用于酶辅助提取过程的酶。相反,VLP含有少数宿主细胞蛋白和与植物脂质筏相关的葡糖基胺。鉴定这种筏标记物,与鉴定的宿主细胞杂质的类型一起证实,Planta中VLP形成的机制类似于哺乳动物中流感病毒组件的自然过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号